These findings suggest that MBI is closely aligned with the NIA-AA Core 1 biomarkers (amyloid and phosphorylated tau pathology defining the AD continuum) [75], strengthening its potential role in early detection and guiding timely diagnostic evaluation. The gene discussed is MAPT; the disease is Alzheimer disease.